Clinical Trials Logo

Tuberculosis, Pulmonary clinical trials

View clinical trials related to Tuberculosis, Pulmonary.

Filter by:

NCT ID: NCT04919239 Not yet recruiting - Clinical trials for Tuberculosis, Pulmonary

Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)

Start date: September 2021
Phase: Phase 2
Study type: Interventional

Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB (Multidrug-resistant) patients favourably responding to standard MDR-TB treatment. Time point of vaccination starts upon completion of 1 week of standard DS-TB treatment (cohort A), and another cohort of patients will be vaccinated upon completion of 1 month of standard MDR-TB treatment (cohort B). All the patients will be followed up to the end of the treatment.

NCT ID: NCT04874948 Not yet recruiting - Tuberculosis Clinical Trials

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

Start date: July 2021
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 in 4 healthy adult male subjects

NCT ID: NCT04865536 Recruiting - Tuberculosis Clinical Trials

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Start date: February 16, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT ID: NCT04857814 Not yet recruiting - Cystic Fibrosis Clinical Trials

Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases

Start date: May 2021
Phase: N/A
Study type: Interventional

Lung diseases are one of the most common causes of emergency room visits. There are very few tools that are able to predict which patients will have a worsening or increasing severity of their condition. There are also limited ways to check the health of patients with respiratory conditions at home and during the time between medical appointments. The ADAMM-RSMTM device records heart rate, breathing rate, temperature, cough and activity while wearing it. This study will test participants willingness to wear the device and perform ongoing monitoring to assess the possibility to predict the onset and increases in severity of their lung conditions.

NCT ID: NCT04856644 Not yet recruiting - Clinical trials for Tuberculosis, Pulmonary

Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

ESCAPE-TB
Start date: May 1, 2021
Phase: Phase 3
Study type: Interventional

The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates. This prospective, 3-year, single arm study is to evaluate the efficacy and safety of a short-course, 4-month regimen including isoniazid(H), pyrazinamide(P), rifapentine (P), and moxifloxacin(M) (2HZPM/2HPM) for the treatment of drug-susceptible, pulmonary tuberculosis, and compared with a historical control group receiving the standard six-month regimen.

NCT ID: NCT04848246 Completed - Clinical trials for Tuberculosis, Pulmonary

Effect of Smoking Cessation on Tuberculosis Treatment Outcomes

Start date: November 6, 2017
Phase: N/A
Study type: Interventional

This study was a Randomized Controlled Trial conducted at Ojha Institute of Chest Diseases, Dow University of Health Sciences, Karachi, among pulmonary tuberculosis patients

NCT ID: NCT04844502 Recruiting - Quality of Life Clinical Trials

Cardiopulmonary Function and Quality of Life in Pulmonary Tuberculosis

Start date: April 7, 2021
Phase: N/A
Study type: Interventional

This work aims to assess cardiopulmonary function and quality of life in people with sequelae of pulmonary tuberculosis undergoing rehabilitation. It is an experimental clinical study, with evaluation before and after the intervention. Included participants will be randomized and divided into a control group and an intervention group. Quality of life is examined by two questionnaires and physical fitness by specific tests, before and after the intervention. The intervention is the realization of a supervised physical exercise protocol.

NCT ID: NCT04813666 Completed - Clinical trials for TB - Tuberculosis HIV

Lipoarabinomannan (LAM) in Urine for Diagnosis of Pulmonary Tuberculosis in HIV Patients

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

A diagnostic validity study in which urinary LAM was done in seropositive HIV patients with symptoms suggestive of TB who were included and investigated with battery of tests to reach the final diagnosis.

NCT ID: NCT04783727 Recruiting - Clinical trials for Bacterial Infections

PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

PredictEndTB signature is a non-inferiority, prospective, parallel-group open-label randomized controlled trial evaluating the efficacy of individualised antituberculous treatment durations that utilize the transcriptomic signature-based model compared to the standardised twenty months treatment in a cohort of multidrug-resistant tuberculosis patients.

NCT ID: NCT04766307 Recruiting - Clinical trials for Tuberculosis, Pulmonary

A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Start date: July 20, 2016
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.